Pregnancy Miracle

Pregnancy Miracle By Lisa

Get Instant Access

1. Im SS, Gordon AN, Buttin BM, et al: Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 105(1):35-41, 2005.

2. Ries LAG, Harkins D, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute. (Accessed August 2006).

3. Brinton LA, Lamb EJ, Moghissi KS, et al: Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 82(2):405-414, 2004.

4. Rossing MA, Tang MT, Flagg EW, et al: A case-control study of ovarian cancer in relation to infertility and the use of ovula-tion-inducing drugs. Am J Epidemiol 160(11): 1070-1078,


5. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3):321-333, 2002.

6. Rubin SC, Blackwood MA, Bandera C, et al: BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 178(4):670-677, 1998.

7. Risch HA, McLaughlin JR, Cole DE, et al: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68(3):700-710, 2001.

8. Pal T, Permuth-Wey J, Betts JA, et al: BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104(12):2807-2816, 2005.

9. Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336(20):1401-1408, 1997.

10. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62(3):676-689, 1998.

11. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117-1130, 2003.

12. Dunlop MG, Farrington SM, Carothers AD, et al: Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6(1):105-110, 1997.

13. Aarnio M, Sankila R, Pukkala E, et al: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81(2):214-218, 1999.

14. Kerlikowske K, Brown JS, Grady DG: Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 80(4):700-707, 1992.

15. Stratton JF, Pharoah P, Smith SK, et al: A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 105(5):493-499, 1998.

16. Bergfeldt K, Rydh B, Granath F, et al: Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet 360(9337):891-894, 2002.

17. van Nagell JR, Jr, DePriest PD, Reedy MB, et al: The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 77(3):350-356, 2000.

18. Buys SS, Partridge E, Greene MH, et al: Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 193(5): 1630-1639,


19. Rieber A, Nussle K, Stohr I, et al: Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am J Roentgenol 177(1):123-129, 2001.

20. Timmerman D, Schwarzler P, Collins WP, et al: Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience. Ultrasound Obstet Gynecol 13(1):11-16, 1999.

21. Valentin L: Gray scale sonography, subjective evaluation of the color Doppler image and measurement of blood flow velocity for distinguishing benign and malignant tumors of suspected adnexal origin. Eur J Obstet Gynecol Reprod Biol 72(1):63-72, 1997.

22. Mironov S, Akin O, Pandit-Taskar N, Hann LE: Ovarian cancer. Radiol Clin North Am 45(1):149-166, 2007.

23. Brown DL, Doubilet PM, Miller FH, et al: Benign and malignant ovarian masses: selection of the most discriminating grayscale and Doppler sonographic features. Radiology 208(1): 103-110, 1998.

24. Guerriero S, Alcazar JL, Coccia ME, et al: Complex pelvic mass as a target of evaluation of vessel distribution by color Doppler sonography for the diagnosis of adnexal malignancies: results of a multicenter European study. J Ultrasound Med 21(10):1105-1111, 2002.

25. Salem S, Wilson SR: Gynecologic ultrasound. In Rumack CM, Wilson SR, Charboneau JW, et al (eds): Diagnostic Ultrasound, 2nd ed. Philadelphia: Mosby, 2005.

26. Fleischer AC, Rodgers WH, Rao BK, et al: Assessment of ovarian tumor vascularity with transvaginal color Doppler sonography. J Ultrasound Med 10(10):563-568, 1991.

27. Bourne T, Campbell S, Steer C, et al: Transvaginal colour flow imaging: a possible new screening technique for ovarian cancer. BMJ 299(6712):1367-1370, 1989.

28. Kurjak A, Zalud I, Alfirevic Z: Evaluation of adnexal masses with transvaginal color ultrasound. J Ultrasound Med 10(6):295-297, 1991.

29. Levine D, Feldstein VA, Babcook CJ, Filly RA: Sonography of ovarian masses: poor sensitivity of resistive index for identifying malignant lesions. AJR Am J Roentgenol 162(6): 1355-1359, 1994.

30. Stein SM, Laifer-Narin S, Johnson MB, et al: Differentiation of benign and malignant adnexal masses: relative value of grayscale, color Doppler, and spectral Doppler sonography. AJR Am J Roentgenol 164(2):381-386, 1995.

31. Salem S, White LM, Lai J: Doppler sonography of adnexal masses: the predictive value of the pulsatility index in benign and malignant disease. AJR Am J Roentgenol 163 (5): 11471150, 1994.

32. Jain KA: Prospective evaluation of adnexal masses with endo-vaginal gray-scale and duplex and color Doppler US: correlation with pathologic findings. Radiology 191(1):63-67, 1994.

33. Schelling M, Braun M, Kuhn W, et al: Combined transvaginal B-mode and color Doppler sonography for differential diagnosis of ovarian tumors: results of a multivariate logistic regression analysis. Gynecol Oncol 77(1):78-86, 2000.

34. Hamper UM, Sheth S, Abbas FM, et al: Transvaginal color Doppler sonography of adnexal masses: differences in blood flow impedance in benign and malignant lesions. AJR Am J Roentgenol 160(6):1225-1228, 1993.

35. Rehn M, Lohmann K, Rempen A: Transvaginal ultrasonography of pelvic masses: evaluation of B-mode technique and Doppler ultrasonography. Am J Obstet Gynecol 175(1):97-104, 1996.

36. Brown DL, Frates MC, Laing FC, et al: Ovarian masses: can benign and malignant lesions be differentiated with color and pulsed Doppler US? Radiology 190(2):333-336, 1994.

37. Buy JN, Ghossain MA, Hugol D, et al: Characterization of adnexal masses: combination of color Doppler and conventional sonography compared with spectral Doppler analysis alone and conventional sonography alone. AJ R Am J Roentgenol 166(2):385-393, 1996.

38. Kinkel K, Hricak H, Lu Y, et al: US characterization of ovarian masses: a meta-analysis. Radiology 217(3):803-811, 2000.

39. Cohen LS, Escobar PF, Scharm C, et al: Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 82(1):40^8, 2001.

40. Kurjak A, Kupesic S, Sparac V, Bekavac I: Preoperative evaluation of pelvic tumors by Doppler and three-dimensional sonography. J Ultrasound Med 20(8):829-840, 2001.

41. Kurjak A, Kupesic S, Sparac V, et al: The detection of stage I ovarian cancer by three-dimensional sonography and power Doppler. Gynecol Oncol 90(2):258-264, 2003.

42. Medl M, Kulenkampff KJ, Stiskal M, et al: Magnetic resonance imaging in the preoperative evaluation of suspected ovarian masses. Anticancer Res 15(3):1123-1125, 1995.

43. Yamashita Y, Torashima M, Hatanaka Y, et al: Adnexal masses: accuracy of characterization with transvaginal US and precon-trast and postcontrast MR imaging. Radiology 194(2):557-565, 1995.

44. Komatsu T, Konishi I, Mandai M, et al: Adnexal masses: transvaginal US and gadolinium-enhanced MR imaging assessment of intratumoral structure. Radiology 198(1):109-115, 1996.

45. Kurtz AB, Tsimikas JV, Tempany CM, et al: Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis—report of the Radiology Diagnostic Oncology Group. Radiology 212(1):19-27, 1999.

46. Hricak H, Chen M, Coakley FV, et al: Complex adnexal masses: detection and characterization with MR imaging-multivariate analysis. Radiology 214(1):39—46, 2000.

47. Sohaib SA, Sahdev A, Van Trappen P, et al: Characterization of adnexal mass lesions on MR imaging. AJR Am J Roentgenol 180(5):1297-1304, 2003.

48. Kinkel K, Lu Y, Mehdizade A, et al: Indeterminate ovarian mass at US: incremental value of second imaging test for characterization-meta-analysis and Bayesian analysis. Radiology 236(1):85-94, 2005.

49. Tempany CM, Zou KH, Silverman SG, et al: Staging of advanced ovarian cancer: comparison of imaging modalities— report from the Radiological Diagnostic Oncology Group. Radiology 215(3):761-767, 2000.

50. Byrom J, Widjaja E, Redman CW, et al: Can pre-operative computed tomography predict resectability of ovarian carcinoma at primary laparotomy? BJOG 109(4):369-375, 2002.

51. Kawamoto S, Urban BA, Fishman EK: CT of epithelial ovarian tumors. Radiographics Spec No:S85-S102; quiz S103-S104, 1999.

52. Buy JN, Ghossain MA, Sciot C, et al: Epithelial tumors of the ovary: CT findings and correlation with US. Radiology 178(3): 811-818, 1991.

53. Ghossain MA, Buy JN, Ligneres C, et al: Epithelial tumors of the ovary: comparison of MR and CT findings. Radiology 181(3):863-870, 1991.

54. Subhas N, Patel PV, Pannu HK, et al: Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics 25(4):1031-1043, 2005.

55. Pannu HK, Bristow RE, Cohade C, et al: PET-CT in recurrent ovarian cancer: initial observations. Radiographics 24(1):209-223, 2004.

56. Antoch G, Freudenberg LS, Stattaus J, et al: Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR Am J Roentgenol 179(6):1555-1560, 2002.

57. Dizendorf EV, Treyer V, Von Schulthess GK, Hany TF: Application of oral contrast media in coregistered positron emission tomography-CT. AJR Am J Roentgenol 179(2):477-481, 2002.

58. Fenchel S, Grab D, Nuessle K, et al: Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 223(3):780-788, 2002.

59. Jung SE, Lee JM, Rha SE, et al: CT and MR imaging of ovarian tumors with emphasis on differential diagnosis. Radiographics 22(6):1305-1325, 2002.

60. Occhipinti KA: Computed tomography and magnetic resonance imaging of the ovary. In Anderson JC (eds) Gynecologic Imaging. London: Churchill Livingstone, 1999, pp 345-359.

61. Fukuda T, Ikeuchi M, Hashimoto H, et al: Computed tomography of ovarian masses. J Comput Assist Tomogr 10(6):990-996, 1986.

62. Exacoustos C, Romanini ME, Rinaldo D, et al: Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol 25(1):50-59, 2005.

63. Wagner BJ, Buck JL, Seidman JD, McCabe KM: From the archives of the AFIP. Ovarian epithelial neoplasms: radiologic-pathologic correlation. Radiographics 14(6):1351-1374; quiz 1375-1376, 1994.

64. Wu TT, Coakley FV, Qayyum A, et al: Magnetic resonance imaging of ovarian cancer arising in endometriomas. J Comput Assist Tomogr 28(6):836-838, 2004.

65. Matsuoka Y, Ohtomo K, Araki T, et al: MR imaging of clear cell carcinoma of the ovary. Eur Radiol 11(6):946-951, 2001.

66. Outwater EK, Siegelman ES, Hunt JL: Ovarian teratomas: tumor types and imaging characteristics. Radiographics 21(2):475^90, 2001.

67. Brammer HM III, Buck JL, Hayes WS, et al: From the archives of the AFIP. Malignant germ cell tumors of the ovary: radio-logic-pathologic correlation. Radiographics 10(4) :715-724, 1990.

68. Kim SH, Kang SB: Ovarian dysgerminoma: color Doppler ultrasonographic findings and comparison with CT and MR imaging findings. J Ultrasound Med 14(11):843-848, 1995.

69. Tanaka YO, Kurosaki Y, Nishida M, et al: Ovarian dysgermi-noma: MR and CT appearance. J Comput Assist Tomogr 18(3):443-448, 1994.

70. Ko SF, Wan YL, Ng SH, et al: Adult ovarian granulosa cell tumors: spectrum of sonographic and CT findings with pathologic correlation. AJR Am J Roentgenol 172(5):1227-1233, 1999.

71. Outwater EK, Wagner BJ, Mannion C, et al: Sex cord-stromal and steroid cell tumors of the ovary. Radiographics 18(6):1523-1546, 1998.

72. Morikawa K, Hatabu H, Togashi K, et al:. Granulosa cell tumor of the ovary: MR findings. J Comput Assist Tomogr 21(6):1001-1004, 1997.

73. Bazot M, Ghossain MA, Buy JN, et al: Fibrothecomas of the ovary: CT and US findings. J Comput Assist Tomogr 17(5):754-759, 1993.

74. Troiano RN, Lazzarini KM, Scoutt LM, et al: Fibroma and fibrothecoma of the ovary: MR imaging findings. Radiology 204(3):795-798, 1997.

75. Kim SH, Sim JS, Seong CK: Interface vessels on color/power Doppler US and MRI: a clue to differentiate subserosal uterine myomas from extrauterine tumors. J Comput Assist Tomogr 25(1):36^2, 2001.

76. Torashima M, Yamashita Y, Matsuno Y, et al: The value of detection of flow voids between the uterus and the leiomyoma with MRI. J Magn Reson Imaging 8(2):427-431, 1998.

77. Kim SH, Kim YJ, Park BK, et al: Collision tumors of the ovary associated with teratoma: clues to the correct preoperative diagnosis. J Comput Assist Tomogr 23(6):929-933, 1999.

78. Demopoulos RI, Touger L, Dubin N: Secondary ovarian carcinoma: a clinical and pathological evaluation. Int J Gynecol Pathol 6(2):166-175, 1987.

79. Young RH, Scully RE: Metastatic tumors in the ovary: a problem-oriented approach and review of the recent literature. Semin Diagn Pathol 8(4):250-276, 1991.

80. Mazur MT, Hsueh S, Gersell DJ: Metastases to the female genital tract. Analysis of 325 cases. Cancer 53(9):1978-1984, 1984.

81. Cho KC, Gold BM: Computed tomography of Krukenberg tumors. AJR Am J Roentgenol 145(2):285-288, 1985.

82. Megibow AJ, Hulnick DH, Bosniak MA, Balthazar EJ: Ovarian metastases: computed tomographic appearances. Radiology 156(1):161-164, 1985.

83. Brown DL, Zou KH, Tempany CM, et al: Primary versus secondary ovarian malignancy: imaging findings of adnexal masses in the Radiology Diagnostic Oncology Group Study. Radiology 219(1):213-218, 2001.

84. Dvoretsky PM, Richards KA, Angel C, et al: Survival time, causes of death, and tumor/treatment-related morbidity in 100 women with ovarian cancer. Hum Pathol 19(11):1273-1279, 1988.

85. Ricke J, Sehouli J, Hach C, et al: Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol 13(5):943-949, 2003.

86. Harisinghani MG, Saini S, Weissleder R, et al: MR lymphangi-ography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. AJR Am J Roentgenol 172(5):1347-1351, 1999.

87. Bellin MF, Roy C, Kinkel K, et al: Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall super-paramagnetic iron oxide particles—initial clinical experience. Radiology 207(3):799-808, 1998.

88. Sella T, Rosenbaum E, Edelmann DZ, et al: Value of chest CT scans in routine ovarian carcinoma follow-up. AJR Am J Roentgenol 177(4):857-859, 2001.

89. Forstner R, Hricak H, Occhipinti KA, et al: Ovarian cancer: staging with CT and MR imaging. Radiology 197(3):619-626, 1995.

90. Coakley FV, Choi PH, Gougoutas CA, et al: Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 223(2):495-499, 2002.

91. Stevens SK, Hricak H, Stern JL: Ovarian lesions: detection and characterization with gadolinium-enhanced MR imaging at 1.5 T. Radiology 181(2):481-488, 1991.

92. Qayyum A, Coakley FV, Westphalen AC, et al: Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 96(2): 301-306, 2005.

93. Drieskens O, Stroobants S, Gysen M, et al: Positron emission tomography with FDG in the detection of peritoneal and ret-roperitoneal metastases of ovarian cancer. Gynecol Obstet Invest 55(3):130-134, 2003.

94. Yoshida Y, Kurokawa T, Kawahara K, et al: Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR Am J Roentgenol 182(1):227-233, 2004.

95. Park CM, Kim SH, Kim SH, et al: Recurrent ovarian malignancy: patterns and spectrum of imaging findings. Abdom Imaging 28(3):404-415, 2003.

96. Prayer L, Kainz C, Kramer J, et al: CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer. J Comput Assist Tomogr 7(4):626-632, 1993.

97. Dachman AH, Visweswaran A, Battula R, et al: Role of chest CT in the follow-up of ovarian adenocarcinoma. AJR Am J Roentgenol 176(3):701-705, 2001.

98. Low RN, Saleh F, Song SY, et al: Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination—a longitudinal study. Radiology 211(2):519-528, 1999.

99. Low RN, Duggan B, Barone RM, et al: Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year. Radiology 235(3):918-926, 2005.

100. Garcia Velloso MJ, Boan Garcia JF, Villar Luque LM, et al: [F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125]. Rev Esp Med Nucl 22(4):217-223, 2003.

101. Cho SM, Ha HK, Byun JY, et al: Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. AJR Am J Roentgenol 179(2):391-395, 2002.

102. Sironi S, Messa C, Mangili G, et al: Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with his-tologic findings. Radiology 233(2):433-440, 2004.

103. Kubik-Huch RA, Dorffler W, von Schulthess GK, et al: Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 10(5):761-767, 2000.

104. Bristow RE, del Carmen MG, Pannu HK, et al: Clinically occult recurrent ovarian cancer: patient selection for secondary cyto-reductive surgery using combined PET/CT. Gynecol Oncol 90(3):519-528, 2003.

105. Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW: Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 82(1): 17-21, 2001.

106. Zimny M, Siggelkow W, Schroder W, et al: 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 83(2): 310-315, 2001.

107. Nanni C, Rubello D, Farsad M, et al: (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol 31(7):792-797, 2005.

108. Murakami M, Miyamoto T, Iida T, et al: Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer 16 Suppl 1:99-107, 2006.

109. Torizuka T, Nobezawa S, Kanno T, et al: Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose. Eur J Nucl Med Mol Imaging 29(6):797-803, 2002.

110. Yen RF, Sun SS, Shen YY, et al: Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res 21(5):3691-3694, 2001.

111. Schaffler GJ, Groell R, Schoellnast H, et al: Digital image fusion of CT and PET data sets-clinical value in abdominal/ pelvic malignancies. J Comput Assist Tomogr 24(4):644-647, 2000.

112. Kim S, Chung JK, Kang SB, et al: [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. Eur J Nucl Med Mol Imaging 31(2):196-201, 2004.

113. Smith GT, Hubner KF, McDonald T, Thie JA: Cost analysis of FDG PET for managing patients with ovarian cancer. Clin Positron Imaging 2(2):63-70, 1999.

114. Barranger E, Kerrou K, Petegnief Y, et al: Laparoscopic resection of occult metastasis using the combination of FDG-positron emission tomography/computed tomography image fusion with intraoperative probe guidance in a woman with recurrent ovarian cancer. Gynecol Oncol 96(1):241-244, 2005.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment